Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 7180
- Registration Number
- NCT01575834
- Locations
- 🇬🇧
Research Site, Reading, United Kingdom
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
Phase 3
Completed
- Conditions
- Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 795
- Registration Number
- NCT01575873
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 929
- Registration Number
- NCT01568866
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 121
- Registration Number
- NCT01568216
- Locations
- 🇪🇸
Research Site, Madrid, Spain
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT01568203
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT01568229
- Locations
- 🇬🇧
Research Site, Warrington, United Kingdom
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Phase 4
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: 800 mg ibuprofen/26.6 mg famotidine
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT01563185
- Locations
- 🇺🇸
Dell Children's Medical Center of Central Texas, Austin, Texas, United States
🇺🇸Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Children's Hospital, New Orleans, Louisiana, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT01561963
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Phase 4
Completed
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT01544114
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT01543204
- Locations
- 🇨🇦
Research Site, Waterloo, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath